MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 27th Annual Piper Jaffray Healthcare Conference.
The presentation at the Piper Jaffray conference is scheduled for 9:30 a.m. ET on December 1, 2015 at the New York Palace Hotel in New York.
A replay of each presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replays will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.
XENT-F
